FY3/22

Results Briefing Presentation

May 13, 2022





- FY3/22 Results Summary
- FY3/23 Full-Year Guidance
- Management Issues and Medium-term Business Plan

FY3/22 Results Summary





Net sales +648.7 billion YoY +2.3% FY3/22 results Operating income +34.0 billon YoY -8.8% Store openings 84 stores YoY +33.3%

- Impact of pullback from COVID-19 / stay-at-home demand
- Performance at station front-type stores remained weak
- 84 stores opened new record

Consolidated Income Statement



(millions of yen)

		FY	3/21					FY3/22				
	Results			Results				Guidance			Previous repo	
			Breakdown		Breakdown	YoY change	Vs. guidance		Breakdown	Results	Breakdown	YoY change
Net	sales	634,310	100.0%	648,734	100.0%	2.3%	-1.2%	656,600	100.0%	656,759	100.0%	3.5%
Gross profit		158,550	25.0%	156,506	24.1%	-1.3%	-1.8%	159,330	24.3%	164,218	25.0%	3.6%
,	SG&A expenses	121,204	19.1%	122,454	18.9%	1.0%	-0.1%	122,530	18.7%	130,249	19.8%	7.5%
	Labor cost	51,824	8.2%	53,884	8.3%	4.0%	-0.4%	54,100	8.2%	53,884	8.2%	4.0%
	Selling cost	11,327	1.8%	4,416	0.7%	-61.0%	-2.3%	4,520	0.7%	12,210	1.9%	7.8%
	Administrative expenses	58,051	9.2%	64,154	9.9%	10.5%	0.4%	63,910	9.7%	64,154	9.8%	10.5%
Оре	erating income	37,345	5.9%	34,052	5.2%	-8.8%	-7.5%	36,800	5.6%	33,968	5.2%	-9.0%
Orc	linary income	38,228	6.0%	34,734	5.4%	-9.1%	-7.1%	37,400	5.7%	34,651	5.3%	-9.4%
Net	income	25,329	4.0%	23,853	3.7%	-5.8%	-7.2%	25,700	3.9%			

Overview

- Net sales: Impacted by pullback from pandemic-related demand
- Gross profit: Larger-than-expected pullback for infection prevention products (alcohol disinfectant, hand soap, etc.)
- SG&A expenses: Administrative expenses higher YoY due to systematic implementation of aggressive store opening / major store refurbishment program

 Increase in electricity rates amid rise in crude oil price

Consolidated Income Statement By Business



(millions of yen)

	Drugstore	FY3/21		FY3/22										
	business	Results		Results				Guidance		Reference: Previous reporting basis				
_		Nesuits	Breakdown	n	Breakdown	YoY change	Vs. guidance	Guidance	Breakdown	Results	Breakdown	YoY change		
N	et sales	422,251	100.0%	424,825	100.0%	0.6%	-1.7%	432,140	100.0%	431,981	100.0%	2.3%		
G	oss profit	114,406	27.1%	110,051	25.9%	-3.8%	-2.3%	112,650	26.1%	116,924	27.1%	2.2%		
	SG&A expenses	89,362	21.2%	88,373	20.8%	-1.1%	-0.2%	88,570	20.5%	95,321	22.1%	6.7%		
Ol	erating income	25,043	5.9%	21,677	5.1%	-13.4%	-10.0%	24,080	5.6%	21,603	5.0%	-13.7%		
Oı	dinary income	25,801	6.1%	22,271	5.2%	-13.7%	-9.5%	24,600	5.7%	22,197	5.1%	-14.0%		

Overview

- Suburban-type ⇒ Pullback from surge in demand in FY3/21
- Station front-type ⇒ Continued absence of inbound demand

(millions of yen)

	Discount store	FY3/21		FY3/22										
•	business	Results		Results				Guidance		Reference: Previous reporting basis				
_		Results	Breakdown	Results	Breakdown	YoY change	Vs. guidance	Caraarioo	Breakdown	Results	Breakdown	YoY change		
Ne	t sales	255,714	100.0%	269,885	100.0%	5.5%	-0.3%	270,800	100.0%	270,752	100.0%	5.9%		
Gr	oss profit	44,321	17.3%	46,642	17.3%	5.2%	-0.5%	46,870	17.3%	47,480	17.5%	7.1%		
	SG&A expenses	32,009	12.5%	34,268	12.7%	7.1%	0.3%	34,150	12.6%	35,115	13.0%	9.7%		
Op	erating income	12,312	4.8%	12,374	4.6%	0.5%	-2.7%	12,720	4.7%	12,365	4.6%	0.4%		
Or	dinary income	12,437	4.9%	12,463	4.6%	0.2%	-2.6%	12,800	4.7%	12,454	4.6%	0.1%		

Overview

■ Net sales / profits slightly below guidance, but increased YoY

Store Openings



■ Target achieved on increase in openings of free-standing suburban-type stores

	FY3	/20	FY3	/21		FY	3/22	
	Net	No. of	Net	No. of		-	Net	No. of stores
	increase	stores	increase	stores	Openings	Closures	increase	
Drugstore business	+6	876	+27	903	60	- 17	+43	946
Discount store business	+15	292	+21	313	24	- 2	+22	335
Total	+21	1,168	+48	1,216	84	- 19	+65	1,281

	FY3	3/20	FY	3/21		F`	/ 3/22	
【By area】	Net increase	No. of stores	Net increase	No. of stores	Openings	Closures	Net increase	No. of stores
Hokkaido, Tohoku	+6	109	+5	114	10	-	+10	124
Kanto	+9	395	+13	408	23	- 5	+18	426
Shinetsu, Hokuriku	+0	77	+5	82	6	- 3	+3	85
Tokai	- 4	82	+2	84	8	- 3	+5	89
Kinki	+3	118	+8	126	14	- 2	+12	138
Chugoku, Shikoku	+4	143	+5	149	13	- 3	+10	159
Kyusyu, Okinawa	+3	244	+10	253	10	- 3	+7	260


■ Group total Plan: 84 stores → Actual: 84 stores


[Drugstore business] Plan: 59 stores → Actual: 60 stores [Discount store business] Plan: 25 stores → Actual: 24 stores



Impact of pullback from COVID-19 / stay-at-home demand

Same-store sales growth by business (YoY)





- FY3/21 Sep → Pullback from rise in special demand in previous year ahead of consumption tax hike
- FY3/21 Oct → Rebound from drop in demand in previous year after consumption tax hike
- FY3/21 Feb → Impact from leap year in Feb FY3/20 as well as increase in demand in previous year due to COVID-19

Existing drugstore trends

Full-year -2.3% < station front-type +1.0% suburban type -3.4% >

- Pullback in demand for COVID-19 infection prevention products
- Station front-type: Sales still weak, but higher YoY on fading impact from drop in demand for cosmetics caused by consumers staying home and absence of inbound demand
- Suburban-type: Impact from pullback in stay-at-home demand for food and daily necessities, etc.

Existing discount store trends

Full-year +0.8%

- Impact from pullback in stay-at-home demand for consumer electronics, etc.
- Strong demand for food products

Net Sales By Category



Impact from pullback in demand for infection prevention products / food products and stay-at-home demand

(millions of yen)

	FY3	3/21			FY3	3/22		
Drugstore business	Results		Results				Reference: Previous repo	
	Results	Breakdown	Results	Breakdown	YoY change	Results	Breakdown	YoY change
Health care	128,788	30.5%	126,553	29.8%	-1.7%	128,097	29.7%	-0.5%
Consumables	88,927	21.1%	90,142	21.2%	1.4%	91,246	21.1%	2.6%
Beauty care	126,168	29.9%	131,590	31.0%	4.3%	134,816	31.2%	6.9%
Food	59,477	14.1%	58,511	13.8%	-1.6%	59,322	13.7%	-0.3%
Other	18,890	4.5%	18,026	4.2%	-4.6%	18,498	4.3%	-2.1%
Total	422,251	100.0%	424,825	100.0%	0.6%	431,981	100.0%	2.3%

(millions of yen)

Discount store	FY3/21		FY3/22								
business	Results		Results			Reference	Reference: Previous reporting basis				
- Dusiness	Results	Breakdown	Results	Breakdown	YoY change	Results	Breakdown	YoY change			
Health & Beauty	54,626	21.4%	58,564	21.7%	7.2%	58,776	21.7%	7.6%			
Food	165,790	64.8%	176,371	65.4%	6.4%	176,885	65.3%	6.7%			
Other	35,297	13.8%	34,949	12.9%	-1.0%	35,091	13.0%	-0.6%			
Total	255,714	100.0%	269,885	100.0%	5.5%	270,752	100.0%	5.9%			

Consolidated Balance Sheet



(millions of yen)


FY3/21	(millions of yen)
Total asset: (Equity rat	
Current acceta	Liabilities 103,371 (+5,917)
Current assets 194,262 (+13,075)	Net assets
Long-term assets 114,265 (+11,176)	205,156 (+18,334)

FY3/22	(millions of yen)
Total asset (Equity rat	
Current assets 199,537 (+5,275)	Liabilities 105,175 (+1,803) Net assets
Long-term assets 126,230 (+11,965)	220,592 (+15,436)

+1,731 -3,914 +4,301 -1,190
+1,731 -3,914 +4,301
+1,731 -3,914
+1,731
T320
+928
+629
+650
+10,685
+11,965
+1,694
+51
+693
+2,835
+5,275

Consolidated Cash Flows





FY3/23 Full-Year Guidance





■ Full-year guidance ⇒ Net sales ¥693.6 billion, operating income ¥35.4 billion

(millions of yen)

	Consolidated			Drugstore business			Discount store business			
		Guidance	Breakdown	YoY change	Guidance	Breakdown	YoY change	Guidance	Breakdown	YoY change
Ne	t sales	693,600	100.0%	6.8%	452,000	100.0%	6.4%	290,700	100.0%	7.7%
Gr	oss profit	168,400	24.3%	7.6%	118,500	26.2%	7.7%	50,150	17.3%	7.5%
	SG&A expenses	133,000	19.2%	8.6%	95,700	21.2%	8.3%	37,550	12.9%	9.6%
Op	erating income	35,400	5.1%	4.0%	22,800	5.0%	5.2%	12,600	4.3%	1.8%
Or	dinary income	36,000	5.2%	3.6%	23,350	5.2%	4.8%	12,650	4.4%	1.5%
Ne	t income	24,200	3.5%	1.5%	15,700	3.5%	1.4%	8,500	2.9%	1.5%

■ Earnings per share: ¥206.97

■ Depreciation and amortization: ¥11,900 million

■ Capital investment: ¥29,000 million

■ Dividends: ¥72 (interim ¥36; year-end ¥36)

Group same-store sales YoY forecast

Drugstore business

Discount store business

Full-year: $+0.5 \Rightarrow [1H - 0.1, 2H + 1.2]$

Full-year: $+0.3 \Rightarrow [1H - 0.8, 2H + 1.5]$

Full-year: $+0.8 \Rightarrow [1H +0.9, 2H +0.7]$

Continued negative impact from loss of inbound demand

Store openings: 100

•Drugstore business: 70 (including 5 franchise stores) Discount store business: 30

Refurbishments: 108

Drugstore business: 95 Discount store business: 13

Closures: 15

Assumptions


Drugstore business: 14 Discount store business: 1

Management Issues and Medium-term Business Plan





Targeting consolidated net sales of ¥1 trillion



[Business strategy] Format strategy



Combine formats to cover different sales channels, areas and customer segments

Extend trading areas
Expand target
customer segments
Combine retail formats

Suburban locations

Free-standing store

Local shopping areas

Neighborhood shopping center

Drugstore business

Dispensing pharmacy business



Discount store business

EC digital business

[Business strategy] Store openings



Increase number of store openings

Store development tasks

Drugstore business

Initiatives to further expand chain

Discount store business

Accelerate store openings in East Japan Develop new areas

Response measures

Strengthen property information gathering capabilities

Expand store development team 37 staff as of March 31, 2021

41 staff as of March 31, 2022

53 staff as of March 31, 2023 (plan)

Open more suburban-type stores

Increase openings of free-standing stores

14 stores as of March 31, 2021

30 stores as of March 31, 2022

35 stores as of March 31, 2023 (plan)

Deploy staff to East Japan


Open stores in East Japan

4 stores as of March 31, 2021

7 stores as of March 31, 2022

9 stores as of March 31, 2023 (plan)

*Expected total of 38 stores



[Business strategy] Reinforce EC business



Active in various sales channels

Reinforce e-commerce sales

Offer more products online / expand sales channels

- Increase number of products
- Dec 2021···Store opened in JRE Mall
- Sep 2021····Sales agent outlet opened in Bibian online site
- Store opening planned for LAZADA

Expand in-store pickup service

- · Extend to Hokkaido, Kyushu, Tohoku areas
- Launch Rakuten Ichiba, PayPay Mall services

Marketing

- Realize 1-to-1 marketing by integrating physical and virtual channels
- Develop social media presence and new channels

Improve logistics efficiency

Yokohama / Fukuoka / Sapporo / Saitama / Sendai
 ⇒ Plan to add another site for distribution in Kinki region

Improve customer satisfaction

- Use NPS survey to gauge customer satisfaction
- Improve website usability



Store locations

[Domestic sites] Sundrug e-shop / Rakuten Ichiba / Yahoo! / amazon / au Wowma! / JRE Mall

[Cross-border e-commerce] Tmall Global / Bibian

Targeting stronger growth

Use 1-to-1 marketing Further broaden sales channels Improve customer satisfaction Provide a seamless shopping experience

Increase productivity / reinforce organizational foundations Combine physical and virtual channels

[Business strategy] Strengthen dispensing pharmacy business



■ Initiatives to capture dispensing demand in Japan's aging society

Opening more dispensing pharmacies

As of March 31, 2022 Standalone pharmacies: 31 stores Drugstore pharmacies: 84 stores

Dispensing results FY3/2022

[Prescription drug sales] ¥10,687 million

YoY: +10.3%

[No. of prescriptions] 1,247,553

YoY: +11.8%

[Average prescription price] ¥8,567

YoY: -1.4%

Pharmacy Opening results FY3/22

Opened 2 standalone pharmacies and 11 drugstore pharmacies

FY 3/23

Plan to open 2 standalone pharmacies and 24 drugstore pharmacies

Working to open more dispensing pharmacies

- Stepping up hiring and training to support store opening program
- Online pharmaceutical guidance
 ⇒ Rolling out online pharmaceutical treatment guidance system
- Establishing follow-up system for pharmaceutical treatment
 - Confirm patients are taking necessary medicines



Online pharmaceutical guidance

- Strengthening home healthcare initiatives
 - ⇒ value of prescription delivery demand +41.6%, number of visits +35.4% YoY
 - Cultivating home healthcare pharmacists, stepping up training (internal certification system)
- Introducing LINE MINI app
 - ⇒ Improved prescription communication functionality



LINE MINI app

[Reinforcement of business base] Digitization



Use customer data to increase customer loyalty




Digital-derived sales

Proportion of digital sales: 26.5% (+9.0 ppt YoY)

*Drugstore business FY3/22 results

Retail media business

[No. of transactions] +75.7% YoY [Net sales] +314.5% YoY



[Reinforcement of business base] Improve productivity



Initiatives to further improve operational efficiency

Started introducing electronic shelf labelling

Gross profit +1.0% · labor cost -3.5%

- FY3/22: Introduced at 20 stores
- FY3/23: Planned introduction at 100 stores
- Capital investment: Projected total of roughly ¥25 billion

STEP 1

⇒Reduce in-store work such as attaching sale price tags

STEP 2

Add more functions that further improve productivity

⇒Visualize products for sell-by-date checks / improve efficiency of store operations by visualizing inventories, etc.



Self-scan system

Trial to start in FY3/23

- Smartphone app improves customer convenience and store productivity
 - ⇒Reduces checkout wait-times and time needed to scan products at cash register
 - *Promotes non-contact transactions for the new normal of living with COVID-19



[Reinforcement of business base] Promote sustainability management # SUNDRUG




- **ESG/SDG** initiatives moving from design and launch phase to PDCA cycle phase
- Promote sustainability management > support progress monitoring using KPIs, coordinate with business partners, enhance ESG disclosure

	Category	Progress so far	Outlook
E	Promote environmental management 7 ***********************************	 Introduced eco-friendly PB products Reduced food waste, started building recycling system 	 Introduce solar power and other renewable energy Set targets and implement measures to reduce CO₂ emissions with business partners
S	Promote compliance management 10 APROPER 16 TRUCKS 17 (F-6-7-7) TO HERCELLES 17 (F-6-7-7) TO HERCELLES 18 TO	 Formulated code of conduct, human rights policy Expanded training content and opportunities Started human rights due diligence, CSR procurement 	 Promote "White Logistics" Reinforce operation of internal whistleblower system Extend human rights due diligence, CSR procurement
S	Create motivating workplaces 5 / SEPONT NOTE OF THE SEPONT NOTE OF TH	 Improved flexible work schemes (regional employee / irregular hours systems) Formulated health declaration 	 Encourage employees to take childcare leave, paid leave Empower women in the workplace (managerial positions / train candidates)
S	Support healthy and prosperous lifestyles 3 EXTOR: 8 PROPERTY OF THE PROPERTY	 Trained staff to help people with dementia Introduced Buy Online Pick up In Store (BOPIS) system (4 prefectures in Kanto region) 	 Work closely with local governments / comprehensive community support centers Introduce online pharmaceutical treatment guidance
G	Promote governance management	 Disclosed non-financial data (launched new site, provided data) Conducted analysis of climate-change risk 	 Reinforce information security (policy, training, systems) Publish integrated report
		Launch initiatives	Accelerate initiatives
	Establish promotion framework		

Shareholder Return Policy



■ Dividend policy – Pay stable, continuous dividends based on a dividend payout ratio of 30% or higher



(Note) The Company conducted a 2-for-1 share split of ordinary shares on April 1, 2017

Dividend per share is calculated assuming the share split was conducted at the start of FY3/08

The Company will consider ways of effectively using cash on hand, taking into account required investments such as new store openings and IT systems



Contact

SUNDRUG Co., Ltd. Financial Department

[Address] 1-38-1 Wakamatsu-cho, Fuchu-shi, Tokyo 183-0005

[Phone] 042-369-6211

This document contains information on current business plans, earnings forecasts and projections that constitute forward-looking statements. These forward-looking statements have been formulated based on currently available information and may differ from actual results due to a range of factors. As such, the Company makes no commitment or guarantee that the forecasts in this document will be attained.